Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

34,830 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine (CoronaVac) in healthy adults aged 60 years and older: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial.
Wu Z, Hu Y, Xu M, Chen Z, Yang W, Jiang Z, Li M, Jin H, Cui G, Chen P, Wang L, Zhao G, Ding Y, Zhao Y, Yin W. Wu Z, et al. Lancet Infect Dis. 2021 Jun;21(6):803-812. doi: 10.1016/S1473-3099(20)30987-7. Epub 2021 Feb 3. Lancet Infect Dis. 2021. PMID: 33548194 Free PMC article. Clinical Trial.
Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine (CoronaVac) in healthy children and adolescents: a double-blind, randomised, controlled, phase 1/2 clinical trial.
Han B, Song Y, Li C, Yang W, Ma Q, Jiang Z, Li M, Lian X, Jiao W, Wang L, Shu Q, Wu Z, Zhao Y, Li Q, Gao Q. Han B, et al. Among authors: wu z. Lancet Infect Dis. 2021 Dec;21(12):1645-1653. doi: 10.1016/S1473-3099(21)00319-4. Epub 2021 Jun 28. Lancet Infect Dis. 2021. PMID: 34197764 Free PMC article. Clinical Trial.
Immunogenicity and safety of a third dose of CoronaVac, and immune persistence of a two-dose schedule, in healthy adults: interim results from two single-centre, double-blind, randomised, placebo-controlled phase 2 clinical trials.
Zeng G, Wu Q, Pan H, Li M, Yang J, Wang L, Wu Z, Jiang D, Deng X, Chu K, Zheng W, Wang L, Lu W, Han B, Zhao Y, Zhu F, Yu H, Yin W. Zeng G, et al. Among authors: wu q, wu z. Lancet Infect Dis. 2022 Apr;22(4):483-495. doi: 10.1016/S1473-3099(21)00681-2. Epub 2021 Dec 8. Lancet Infect Dis. 2022. PMID: 34890537 Free PMC article. Clinical Trial.
Efficacy, safety and immunogenicity of hexavalent rotavirus vaccine in Chinese infants.
Wu Z, Li Q, Liu Y, Lv H, Mo Z, Li F, Yu Q, Jin F, Chen W, Zhang Y, Huang T, Hu X, Xia W, Gao J, Zhou H, Bai X, Liu Y, Liang Z, Jiang Z, Chen Y, Zhang J, Du J, Yang B, Xing B, Xing Y, Dong B, Yang Q, Shi C, Yan T, Ruan B, Shi H, Fan X, Feng D, Lv W, Zhang D, Kong X, Zhou L, Que D, Chen H, Chen Z, Guo X, Zhou W, Wu C, Zhou Q, Liu Y, Qiao J, Wang Y, Li X, Duan K, Zhao Y, Xu G, Yang X. Wu Z, et al. Among authors: wu c. Virol Sin. 2022 Oct;37(5):724-730. doi: 10.1016/j.virs.2022.07.011. Epub 2022 Aug 1. Virol Sin. 2022. PMID: 35926726 Free PMC article. Clinical Trial.
Immunogenicity and safety of a new hexavalent rotavirus vaccine in Chinese infants: A randomized, double-blind, placebo-controlled phase 2 clinical trial.
Wu ZW, Jin F, Li QL, Gao JM, Zhou HS, Duan K, Gao Z, Liu Y, Hao ZY, Chen W, Liu YY, Xu GL, Yang B, Dong B, Zhang JW, Zhao YL, Yang XM. Wu ZW, et al. Hum Vaccin Immunother. 2023 Aug;19(2):2263228. doi: 10.1080/21645515.2023.2263228. Epub 2023 Oct 16. Hum Vaccin Immunother. 2023. PMID: 37843437 Free PMC article. Clinical Trial.
Immunogenicity and safety of a SARS-CoV-2 mRNA vaccine (SYS6006) in healthy Chinese participants: A randomized, observer-blinded, placebo-controlled phase 2 clinical trial.
Jin F, Qiu Y, Wu Z, Wang YH, Cai C, Fu L, Jiao W, Wang H, Gao M, Su C, Ma JH, Xu Y, Huang CC, Zhang Q, Ni S, Zhao M, Guo L, Ji L, Yang H, Zhao Y, Li C, Lu X, Su YW, Li Q. Jin F, et al. Among authors: wu z. Vaccine. 2024 Mar 7;42(7):1561-1570. doi: 10.1016/j.vaccine.2024.01.098. Epub 2024 Feb 15. Vaccine. 2024. PMID: 38365485 Clinical Trial.
34,830 results
You have reached the last available page of results. Please see the User Guide for more information.